Cassava Sciences, Inc. (SAVA)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 30.44 |
| Open | 30.50 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1400 |
| Day's range | 29.90 - 31.07 |
| 52-week range | 15.72 - 146.16 |
| Volume | |
| Avg. volume | 1,682,551 |
| Market cap | 1.235B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | N/A |
- Zacks
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $30.44, marking a -1.17% move from the previous day.
- Zacks
Cassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.
- Simply Wall St.
Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Cassava Sciences, Inc.'s (NASDAQ:SAVA) a clinical stage biotechnology company, is developing a drug for Alzheimer - a neurodegenerative disease, affecting more than 35.7 million people worldwide (6 million in the US). In this article, we will review Cassava's product line and cash capacity to fund further research until FDA approval.
© 2022 Yahoo. All rights reserved.
